Alexion Pharmaceuticals said it sold $400.4 million worth of its blockbuster blood disorder drug Soliris in the third quarter, a 36 percent increase compared to the same period last year.
The Cheshire biopharmaceutical company said profits were up 1.7 percent to $93.8 million for the quarter, or 47 cents per diluted share.
The small bump in net income was due to higher costs and expenses related to selling, research and development and acquisitions.
Alexion raised and narrowed its 2013 revenue guidance on the Soliris results, from a previous range of $1.52 billion to $1.53 billion to a range of $1.535 billion to $1.540 billion.
ADVERTISEMENT
It also expects higher earnings per share of between $3.02 and $3.04, up from $2.97 to $3.02.
